Wong, 39,616 patient metformin prophylaxis study: 51% lower mortality [p<0.0001], 41% lower ventilation [p<0.0001], and 40% lower hospitalization [p<0.0001] https://c19p.org/wong2
copied to clipboard
Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National COVID Cohort Collaborative (N3C) Database
et al., Diabetes Care, doi:10.2337/dc21-2186
N3C retrospective 39,616 COVID-19 patients with diabetes in the USA, showing lower mortality, ventilation, and hospitalization with metformin use.
|
risk of death, 51.0% lower, HR 0.49, p < 0.001, treatment 10,408, control 29,208, Cox proportional hazards.
|
|
risk of mechanical ventilation, 41.0% lower, OR 0.59, p < 0.001, treatment 10,408, control 29,208, adjusted per study, multivariable, RR approximated with OR.
|
|
risk of hospitalization, 40.0% lower, OR 0.60, p < 0.001, treatment 10,408, control 29,208, adjusted per study, multivariable, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Wong et al., 2/24/2022, retrospective, USA, North America, peer-reviewed, 15 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.